Using an electronic medical records database from the UK, we conducted a population-based cohort study to compare the risk of recurrent gout flares and all-cause mortality between patients initiating SGLT2i treatment and those initiating 2 other antidiabetic medications (ie, glucagonlike peptide-1 receptor agonists [GLP-1 RA] or dipeptidyl peptidase-4 inhibitors [DPP-4i]) in patients with gout and type 2 diabetes. This evidence concerns the gene DPP4 and gout.